Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 3 respectively.Progressive Multifocal Leukoencephalopathy.
Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Humabs BioMed SA
Neurimmune Holding AG
Neuway Pharma GmbH
Pomona Ricerca SRL
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Progressive Multifocal Leukoencephalopathy Overview 6
Therapeutics Development 7
Pipeline Products for Progressive Multifocal Leukoencephalopathy - Overview 7
Progressive Multifocal Leukoencephalopathy - Therapeutics under Development by Companies 8
Progressive Multifocal Leukoencephalopathy - Pipeline Products Glance 9
Early Stage Products 9
Progressive Multifocal Leukoencephalopathy - Products under Development by Companies 10
Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development 11
Humabs BioMed SA 11
Neurimmune Holding AG 12
Neuway Pharma GmbH 13
Pomona Ricerca SRL 14
Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
EBT-103 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
IkT-001 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
IKT-01427 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
IKT-148009 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
imatinib mesylate - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Monoclonal Antibody for JCV and BKV Infections - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
NI-307 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
NPW-007 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PNJC-1 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Progressive Multifocal Leukoencephalopathy - Dormant Projects 34
Progressive Multifocal Leukoencephalopathy - Product Development Milestones 35
Featured News & Press Releases 35
May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy 35
Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases 36
Aug 16, 2011: Inhibikase Therapeutics Receives FDA Clearance For Phase II Trial Of IkT-001 To Treat JC Virus Infection In Multiple Sclerosis Patients 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39
List of Tables
Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Development, H2 2016 9
Products under Development by Companies, H2 2016 10
Progressive Multifocal Leukoencephalopathy - Pipeline by Humabs BioMed SA, H2 2016 11
Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H2 2016 12
Progressive Multifocal Leukoencephalopathy - Pipeline by Neuway Pharma GmbH, H2 2016 13
Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H2 2016 14
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Target, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Progressive Multifocal Leukoencephalopathy - Dormant Projects, H2 2016 34
List of Figures
Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 9
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Targets, H2 2016 16
Number of Products by Stage and Targets, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Types, H2 2016 22
